MediMedia Managed Markets
Managed Care magazine
P&T Community, The Online Resource for P&T Decision Makers
Login / Register
Join Us  Facebook  Twitter  Linked In
About P&T Journal
Editorial: Sonja Sherritze, Editor
Advertising: Maureen Dwyer Liberti,
    Vice President, Group Publisher

Production: Mary Ellen Curry,
    Director of Production Services

Circulation: Jackie Ott, Circulation Manager

Statement of Purpose
Guidelines for Authors
Editorial Board

Recent Issues

September 2009



Down to the Wire on Health Care Reform

Stakes High for Pharmaceutical Industry Sectors

Despite the contentious nature of the health reform debate in Congress, there is significant support from many groups—such as business and labor—for changing the practice of health care delivery, reducing costs, improving effectiveness, and covering the uninsured.
Stephen Barlas

Thiazolidinediones and Cardiovascular Events in High-Risk Patients with Type-2 Diabetes Mellitus

A Comparison with Other Oral Antidiabetic Agents

In a study of a largely minority population of diabetic Medicaid recipients, rosi­- glitazone (Avandia) was linked to an increase in myocardial infarction and stroke, whereas pioglitazone (Actos) and thiazolidinediones as a class did not show such an association.
Fadia T. Shaya, PhD, MPH; Zhiqiang Lu, BSPharm, PhD Candidate; Kyongsei Sohn, PhD, MBA; and Matthew R. Weir, MD

Therapies for Insomnia and Comorbid Chronic Obstructive Pulmonary Disease with a Focus on Ramelteon (Rozerem)

The authors discuss the relationship between sleep-related disorders and pulmonary disease and summarize the risks and benefits of medications for insomnia: the older benzodiazepine receptor agonists (e.g., flurazepam, temazepam, triazolam); the newer non-benzodiazepine agents (e.g., zolpidem, zaleplon, eszopiclone); and ramelteon, a promising melatonin receptor agonist.
Jack Greenberg, MD, and J. B. Goss, RPh, PhD

Pharmaceutical Approval Update

Topics covered include prasugrel (Effient) for reducing cardiovascular events in patients with acute coronary syndrome; ferumoxytol injection (Feraheme) for iron-deficiency anemia in adults with chronic kidney disease; and dronedarone (Multaq) for the treatment of atrial fibrillation.
Marvin M. Goldenberg, PhD, RPh, MS



Home Sweet Home

David B. Nash, MD, MBA, describes how the “medical home” model might reduce costs associated with chronic conditions.
David B. Nash, MD, MBA

Medication Errors

Paralyzed by Mistakes, Part 1

Preventing Errors with Neuromuscular Blocking Agents

In Part 1 of a two-part series, Matthew Grissinger, RPh, FASCP, reviews how mistakes in giving “high-alert” neuromuscular blocking agents can lead to serious patient harm, including paralysis.
Matthew Grissinger, RPh, FASCP

Prescription: Washington

Congress Examines Criticism of PBMs

Anticompetitive Mergers, Lack of Transparency Cited

Stephen Barlas discusses ways in which Congress might target the lack of transparency and anticompetitive practices of pharmacy benefit managers (PBMs) if it passes health care reform legislation.
Stephen Barlas

New Drugs/Drug News/New Medical Devices

From Extavia to Saphris, P&T presents the latest information about FDA approvals, recalls, and industry updates.

Drug Forecast

Romiplostim (Nplate), a Treatment Option for Immune (Idiopathic) Thrombocytopenic Purpura

Romiplostim (Nplate), a therapeutic option for immune (idiopathic) thrombocytopenic purpura, is reviewed.
Diana Hubulashvili, PharmD, and Nino Marzella, BS, MS, PharmD